Creso Pharma brings marketing and sales of cannaQIX® in-house
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX: CPH, FRA: 1X8) has excelled in the last month in terms of sales and orders for its products, and today the company announced that it is taking over the marketing and sales strategy for cannaQIX®, an initiative that should result in improved profit margins while setting the stage for further new product launches.
This appears to be the logical next step for Creso Pharma as sales gain significant traction.
Strategically, once the sales ramp up it is important to optimise supply chain control in order to maintain client satisfaction while also casting an eye to efficiencies that can be gained, effectively maximising the earnings that can be generated as the top line grows.
Creso Pharma highlighted that it was bringing the marketing and sales function of cannaQIX® in-house, taking over from its commercial partner Doetsch Grether in Switzerland, following a growing trend of direct inbound sales enquiries and interest in cannaQIX® product.
cannaQIX® has established customer base with 2100 points of sale
The product is listed with key wholesalers, reaching over 2,100 points of sales to consumers which are pharmacies, pharmacy networks, drugstores, health nutrition shops and bigger retail shops such as Manor.
Creso is now directly supplying all major wholesalers in the country such as Galexis, Amedis and Voigt.
Creso and Doetsch Grether worked in commercial partnership for over three years with peak sales at wholesale price levels reaching more than CHF 230,000 in 2019.
With Creso now bringing this function in-house, it is able to improve its profit margins for cannaQIX® substantially and can set the stage for further product extensions and new product launches such as cannaDOL® in Switzerland.
Commenting on this development, Creso Pharma commercial director Doctor Gian Trepp said, “We are implementing phase 3 of Creso’s operational launch plan by bringing the marketing and sales function of our products in-house.
"While we are thankful for having benefitted from our partnership with Doetsch Grether, our direct sales model will give Creso the opportunity to expand its profit margins as it enters a new phase of growth.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.